带状疱疹减毒活疫苗有效性评估:英国初级保健数据回顾性队列研究
本研究利用英国初级保健数据库THIN,对70-79岁人群按2013年9月至2016年5月接种状态分组,回顾性匹配队列随访平均1.2年。结果显示接种组带状疱疹风险低于未接种组,疫苗有效性为65.3%,预防带状疱疹后神经痛的有效性为72%。
要点
- 接种组带状疱疹发生率为2.95/1000人年,未接种组为8.02/1000人年。
- 带状疱疹疫苗有效性为65.3%(95%CI:60.3-69.6%)。
- 预防带状疱疹后神经痛有效性为72%(95%CI:50.0-83.9%)。
核心结论
- 带状疱疹减毒活疫苗降低了老年人群带状疱疹风险,且鉴于带状疱疹及带状疱疹后神经痛对生活质量的影响,接种获益明确;英国该人群接种率有待提高。
研究设计与样本
- 回顾性匹配队列研究,使用英国初级保健数据库THIN,纳入70-79岁人群,按2013年9月至2016年5月接种状态分类,随访平均1.2年。
主要发现
- 总队列n=295,135,其中接种70,867人(24%),未接种224,268人(76%)。
- 2435例(0.83%)发生带状疱疹:接种组241例(0.34%),未接种组2194例(0.98%)。
- 带状疱疹发病率接种组2.95(95%CI:2.59-3.34)/1000人年 vs 未接种组8.02(95%CI:7.68-8.36)/1000人年。
- 带状疱疹后神经痛风险接种组0.02% vs 未接种组0.06%;发病率接种组0.16(95%CI:0.08-0.27)/1000人年 vs 未接种组0.53(95%CI:0.44-0.62)/1000人年。
关键数值与推荐
- 带状疱疹疫苗有效性65.3%(95%CI:60.3-69.6%),计算方式为1-相对风险(RR)。
- 带状疱疹后神经痛疫苗有效性72%(95%CI:50.0-83.9%)。
临床怎么用
- 英国国家免疫规划为70-79岁成人提供带状疱疹减毒活疫苗;研究期间符合条件队列的接种覆盖率通常为50-60%。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Herpes zoster (shingles) is a common viral disease increasing in risk and severity with age. Post-herpetic neuralgia (PHN), a complication of shingles, causes severe pain impacting quality of life (QoL). Zoster Vaccine Live (ZVL), a licensed vaccine for the prevention of shingles in the United Kingdom (UK), is part of the national immunisation programme (NIP) for adults aged 70-79. Public Health England (PHE) reports show shingles vaccine coverage varies, but is typically 50-60% across eligible cohorts. MATERIALS/METHODS: This retrospective, matched cohort study was conducted using The Health Improvement Network (THIN) UK primary care database. Individuals aged 70-79 were classified based on their vaccination status between September 2013 and May 2016. Risk and incidence rates for shingles were calculated for both groups over the duration of the study (mean 1.2 years). Vaccine effectiveness (VE) was calculated using the equation 1-relative risk (RR) for shingles and PHN. RESULTS: Within the total cohort (n = 295,135), 70,867 (24%) were vaccinated and 224,268 (76%) were unvaccinated. 2435 (0.83%) patients developed shingles: 241 (0.34%) among the vaccinated and 2194 (0.98%) among the unvaccinated. The VE for preventing shingles was 65.3% (95% CI: 60.3-69.6%). The incidence rate in the vaccinated group was 2.95 (95% CI: 2.59-3.34) vs 8.02 (95% CI: 7.68-8.36) per 1000 person years in the unvaccinated group. Risk of PHN was 0.02% and 0.06% in the respective vaccinated and unvaccinated groups. The VE for preventing PHN was 72% (95% CI: 50.0-83.9%). PHN incidence rates were 0.16 (95% CI: 0.08-0.27) and 0.53 (95% CI: 0.44-0.62) per 1000 person years in the vaccinated and unvaccinated groups, respectively. CONCLUSIONS: ZVL reduced the risk of shingles among an elderly population. Given the negative impact of shingles and PHN on QoL, the benefits of vaccination are clear. Improving uptake in the UK is needed in this population.
引用
- Matthews I, Lu X, Dawson H, et al. Assessing the effectiveness of zoster vaccine live: A retrospective cohort study using primary care data in the United Kingdom. Vaccine. 2018. PMID: 30195489. doi:10.1016/j.vaccine.2018.08.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。